FDA Approves Fougera’s Clotrimazole Cream USP 1%

MELVILLE, N.Y., Sept. 12 — Fougera, a division of Nycomed
US Inc., today announced the FDA has approved its Clotrimazole Cream USP
1%. The generic formulation compares to Taro’s Referenced Listed Drug (RLD)
and is available in three sizes: 15g tubes (NDC # 0168-0133-15), 30g tubes
(NDC # 0168-0133-30) and 45g tubes (NDC # 0168-0133-46).

“The approval of Clotrimazole Cream is another illustration of
Fougera’s robust product pipeline,” stated David Klaum, Senior Vice
President and General Manager Fougera. “With each product approval, Fougera
reaffirms its commitment to providing safe, effective and affordable
options to health care providers and their patients.”

About Fougera

Founded in 1849, Fougera is a division of Nycomed US Inc. and is the
leading manufacturer and distributor of a wide range of topical products.
For more information on Fougera’s complete line of products, please call
Fougera Customer Service at (800) 645-9833 or visit the company online at
http://www.fougera.com.

About Nycomed US Inc.

Nycomed US Inc. is a subsidiary of Nycomed. In addition to Fougera,
Nycomed US Inc. operates two additional divisions of specialty
pharmaceuticals. The PharmaDerm(R) division is dedicated to bringing
innovative products to dermatologists so they can best care for their
patients. Nycomed US Inc. also markets and sells Savage Laboratories
products, which focus on emergency care. More information is available at
http://www.nycomedus.com.

SOURCE Fougera